TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9556902

Group type: EXPERIMENTAL
Intervention: Patch containing 4.0 mg of E2 in a reservoir system
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patch containing 1.8 mg of E2 in a specially designed matrix system
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Matrix system patches
Number of subjects: 10
Study: 7575171

Group type: EXPERIMENTAL
Intervention: Paracentesis with Dextran‐70
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 20
Study: 2623709

Group type: EXPERIMENTAL
Intervention: Zinc‐Fluorid‐Hexetidin mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidin (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental gingivitis (negative control)
Number of subjects: 0
Study: 31339815

Group type: EXPERIMENTAL
Intervention: Outpatient burnout prevention program (three-week duration, including stress management interventions, relaxation, physical exercise, moor baths, and massage)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Outpatient burnout prevention program
Number of subjects: 80
Study: 31722135

Group type: EXPERIMENTAL
Intervention: High doses of α-lipoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α-lipoic acid
Number of subjects: 0
Study: 28118185

Group type: EXPERIMENTAL
Intervention: PAD lesions
Number of subjects: 50
Study: 25904367

Group type: EXPERIMENTAL
Intervention: Weekly rifapentine plus isoniazid (3HP)
Number of subjects: 7552

Group type: COMPARATOR
Intervention: Daily isoniazid (9H)
Number of subjects: 7552
Study: 23908125

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 21212920

Group type: EXPERIMENTAL
Intervention: Knowledge assessment regarding Ecstasy (MDMA)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Attitude assessment regarding Ecstasy (MDMA)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Practice assessment regarding Ecstasy (MDMA)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Correlation between knowledge and attitude
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Correlation between attitude and practice
Number of subjects: 4116
Study: 19552744

Group type: EXPERIMENTAL
Intervention: Rabeprazole (7 days) with antibiotics (clarithromycin and amoxicillin) given on days 1-4, 4-7, or 1-7
Number of subjects: 100
Study: 17653421

Group type: EXPERIMENTAL
Intervention: Computer-assisted training (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional classroom training (Group A)
Number of subjects: 60
Study: 15497665

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg test tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg test tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference tablets of the same strength (250 mg and 500 mg)
Number of subjects: 0
Study: 11456368

Group type: EXPERIMENTAL
Intervention: 89Sr‐chloride (527 treatments)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: 186Re‐HEDP (83 treatments)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Retreatments (up to five injections, 100 total)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Retreatments
Number of subjects: 510
Study: 10923463

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered at 60 seconds
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rocuronium maintenance (either intravenous infusion or bolus injection)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered at 90 seconds
Number of subjects: 32
Study: 8038351

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 28
Study: 2499730

Group type: EXPERIMENTAL
Intervention: ubinon (90 and 135 mg/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ubinon
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 31829404

Group type: EXPERIMENTAL
Intervention: Primary tumour resection plus chemotherapy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 280
Study: 31200891

Group type: EXPERIMENTAL
Intervention: Exercise plus education
Number of subjects: 625

Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 625
Study: 27443525

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management program (MDP)
Number of subjects: 355

Group type: COMPARATOR
Intervention: No MDP
Number of subjects: 355
Study: 25863601

Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Avoidance support
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Avoidance Support Measure
Number of subjects: 131
Study: 24151394

Group type: EXPERIMENTAL
Intervention: Triple therapy alone (O‐G+t group)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Triple therapy and mouthrinse treatment (O+G+tm group)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Triple therapy, mouthrinse, and periodontal treatment (O+G+tmp group)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (volunteers without discomfort)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: O‐G+t group
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: O+G+t group
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: O+G+tm group
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: O+G+tmp group
Number of subjects: 391
Study: 21334096

Group type: EXPERIMENTAL
Intervention: Griseofulvin (mean duration of treatment 8 weeks, range 6‐12 weeks)
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Terbinafine (mean duration of treatment 4 weeks, range 2‐6 weeks)
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 2163
Study: 19815540

Group type: EXPERIMENTAL
Intervention: dobutamine 2.5‐5.0 microg/kg/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: control
Number of subjects: 14
Study: 17083726

Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe asthmatics on inhaled steroid treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 39
Study: 15617307

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (BID) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% three times daily (TID) for 4 weeks
Number of subjects: 20
Study: 11360849

Group type: EXPERIMENTAL
Intervention: Modified and vertical maternal position (sitting and prone)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 56
Study: 9258155

Group type: EXPERIMENTAL
Intervention: Varicocele repair
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 124
Study: 7871001

Group type: EXPERIMENTAL
Intervention: tropisetron 0.5 mg daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: tropisetron 25 mg daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: tropisetron (all doses)
Number of subjects: 91
Study: 3531149

Group type: EXPERIMENTAL
Intervention: Somofillina Ritardo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Other slow-release theophylline formulation
Number of subjects: 20
Study: 30613992

Group type: EXPERIMENTAL
Intervention: PICC removal and PN discontinuation at an enteral feed volume of 100 mL/kg/day
Number of subjects: 139

Group type: COMPARATOR
Intervention: PICC removal and PN discontinuation at an enteral feed volume of 140 mL/kg/day
Number of subjects: 139
Study: 29685112

Group type: EXPERIMENTAL
Intervention: Social network intervention (training influential adolescents to promote physical activity)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 190
Study: 24567316

Group type: EXPERIMENTAL
Intervention: Antimony plus pentoxifylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antimony plus placebo
Number of subjects: 0
Study: 22001758

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with tidal volume (V(T)) of 12 mL/kg ideal body weight with zero positive end‐expiratory pressure (PEEP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mechanical ventilation with tidal volume (V(T)) of 6 mL/kg ideal body weight with PEEP of 8 cm H(2)O
Number of subjects: 26
Study: 20810669

Group type: EXPERIMENTAL
Intervention: Metformin (250 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 26
Study: 17953380

Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup A)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup B)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup C)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (subgroup D)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Preoperative preparation method of sequential thyroid defunctionalization (test group)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Antithyroid drugs and iodine preparation (control group)
Number of subjects: 476
Study: 12062146

Group type: EXPERIMENTAL
Intervention: US bird experts
Number of subjects: 3

Group type: COMPARATOR
Intervention: US undergraduates
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ordinary Itza' Maya
Number of subjects: 3
Study: 10219883

Group type: EXPERIMENTAL
Intervention: rec-GH therapy (C=0.6 IU/kg/week for C, CO=0.5 IU/kg/week, A=0.25 IU/kg/week) for 12 months (C and A) and 6 months (CO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: rec-GH therapy
Number of subjects: 35
Study: 7838494

Group type: EXPERIMENTAL
Intervention: Single distal screw
Number of subjects: 178

Group type: COMPARATOR
Intervention: Two distal screws
Number of subjects: 178
Study: 1619179

Group type: COMPARATOR
Intervention: Placebo or different levels of supplemental vitamins
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thiamin intake greater than or equal to 1.0 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake at the current recommended dietary allowance (1.6 mg)
Number of subjects: 18
Study: 6322681

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg per day in two doses for a minimum of 10 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional therapy (ampicillin and chloramphenicol or gentamicin, pending sensitivity)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 45
Study: 30967642

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) high in dietary fiber and whole grain
Number of subjects: 181

Group type: COMPARATOR
Intervention: Average Danish (Western) Diet (ADD)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 181
Study: 30216526

Group type: EXPERIMENTAL
Intervention: smartphone platform intervention with CHW reinforcement
Number of subjects: 98

Group type: COMPARATOR
Intervention: usual prenatal care and printed educational materials (Control)
Number of subjects: 98
Study: 25072436

Group type: EXPERIMENTAL
Intervention: DJBL treatment with dietary intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Dietary intervention (control)
Number of subjects: 77
Study: 23731980

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 0
Study: 20629545

Group type: EXPERIMENTAL
Intervention: Ortho/EMD/DFDBA
Number of subjects: 47

Group type: COMPARATOR
Intervention: EMD/DFDBA
Number of subjects: 47
Study: 17507105

Group type: EXPERIMENTAL
Intervention: sarpogrelate (300 mg/day) plus aspirin (100 mg/day)
Number of subjects: 450

Group type: COMPARATOR
Intervention: ticlopidine (200 mg/day) plus aspirin (100 mg/day)
Number of subjects: 450
Study: 15963687

Group type: EXPERIMENTAL
Intervention: Group voice therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no voice therapy)
Number of subjects: 20
Study: 12959938

Group type: EXPERIMENTAL
Intervention: Type 2 DM with fatty liver
Number of subjects: 83

Group type: COMPARATOR
Intervention: Type 2 DM without fatty liver
Number of subjects: 83
Study: 10664525

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor MPV 2213ad, single dose of 100mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor MPV 2213ad
Number of subjects: 16
Study: 7640644

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1) administered 2‐1/2 hrs prior to swim trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered 2‐1/2 hrs prior to swim trial
Number of subjects: 0
Study: 2665027

Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.0012 mg/kg/day) solution bid for one week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.075 mg/kg/day) solution tid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 363071

Group type: EXPERIMENTAL
Intervention: Butacote (enteric-coated phenylbutazone) 300 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Naprosyn (naproxen) 750 mg daily
Number of subjects: 25
Study: 30408722

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 969

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study: 29229103

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 μg BID
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Formoterol DPI 9 μg BID
Number of subjects: 1219
Study: 26317285

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 24707612

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS) plate
Number of subjects: 32
Study: 21996470

Group type: EXPERIMENTAL
Intervention: Intervention group (n=558)
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Control group (n=449)
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Control group (n=451)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Intervention group (n=532)
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Control group (n=423)
Number of subjects: 1696
Study: 18433672

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.2% ropivacaine 10 mL/h (group R, n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Epidural infusion of 0.9% NaCl 10 mL/h (group S, n = 22)
Number of subjects: 44
Study: 16555138

Group type: EXPERIMENTAL
Intervention: Gluten-free and casein-free diet (GFCF)
Number of subjects: 15
Study: 14556808

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with untreated endometriosis
Number of subjects: 76

Group type: COMPARATOR
Intervention: Peritoneal fluid IL-18 levels in control women
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with superficial peritoneal implants
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with deep peritoneal implants
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with endometriomas
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with stage I-II endometriosis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in women with stage III-IV endometriosis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid IL-18 levels in luteal phase
Number of subjects: 76
Study: 11073017

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g elemental calcium daily)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Fibre supplementation (3.5 g ispaghula husk)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 8882920

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (CBT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-focussed intervention (NFI)
Number of subjects: 56
Study: 8398526

Group type: EXPERIMENTAL
Intervention: lumbar extradural analgesia using 0.5% bupivacaine 1 mg kg‐1 plus morphine 50 micrograms kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: morphine 100 micrograms kg‐1 i.m.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: subpubic block using 0.5% bupivacaine 0.5 mg kg‐1 for each side
Number of subjects: 30
Study: 3768764

Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms X kg‐1 X min‐1 for four minutes, then 300 micrograms X kg‐1 X min‐1 for 8 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 29675767

Group type: EXPERIMENTAL
Intervention: Youth with autism spectrum disorder (ASD)
Number of subjects: 123
Study: 27589605

Group type: EXPERIMENTAL
Intervention: Problem-based learning
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Case-based teaching
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional methodology
Number of subjects: 74
Study: 24991030

Group type: EXPERIMENTAL
Intervention: Noninvasive repetitive transorbital alternating current stimulation (rtACS; 10 days, 40 minutes daily; n = 7)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation (n = 8)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients with partial optic nerve damage
Number of subjects: 28
Study: 22910840

Group type: EXPERIMENTAL
Intervention: Second line therapy (platinum combination, n = 313, 24.5%)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Third line therapy (topotecan, n = 118, 23.6%)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Fourth line therapy
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Fifth line therapy
Number of subjects: 1620
Study: 20523215

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Peripheral nerve stimulator
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Difference between peripheral nerve stimulator and acceleromyography
Number of subjects: 61
Study: 18677171

Group type: EXPERIMENTAL
Intervention: 40-min exercise training sessions
Number of subjects: 134

Group type: COMPARATOR
Intervention: 60-min exercise training sessions
Number of subjects: 134
Study: 15976235

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carbamazepine 100 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12612947

Group type: EXPERIMENTAL
Intervention: EPO plus KAs plus LPD (group I)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: EPO plus LPD (group II)
Number of subjects: 186

Group type: COMPARATOR
Intervention: LPD (group III)
Number of subjects: 186
Study: 10491228

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with spine fractures
Number of subjects: 642

Group type: COMPARATOR
Intervention: Postmenopausal women without spine fractures
Number of subjects: 642

Group type: COMPARATOR
Intervention: Matched by aBMD
Number of subjects: 642

Group type: COMPARATOR
Intervention: Matched by vertebral volume
Number of subjects: 642
Study: 9085622

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg IV after 500 ml of enteral nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ranitidine 50 mg IV after 500 ml of enteral nutrition
Number of subjects: 24
Study: 1716935

Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 32

Group type: COMPARATOR
Intervention: Stable strontium (placebo)
Number of subjects: 32
Study: 6354113

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Erythromycin-neomycin-cefazolin
Number of subjects: 119
Study: 30329102

Group type: EXPERIMENTAL
Intervention: Tobacco advertisement liking
Number of subjects: 9109

Group type: EXPERIMENTAL
Intervention: Lower educational attainment
Number of subjects: 9109

Group type: EXPERIMENTAL
Intervention: Living below the poverty level
Number of subjects: 9109
Study: 30150397

Group type: EXPERIMENTAL
Intervention: Adventure game
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Puzzle game
Number of subjects: 320

Group type: COMPARATOR
Intervention: Text-based education
Number of subjects: 320

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 320
Study: 26864124

Group type: EXPERIMENTAL
Intervention: Liraglutide (not specified dosage or duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment intensity (insulin, statins, oral antihypertensive drugs)
Number of subjects: 0
Study: 24499445

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints on the disease-affected meridian (DAM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Acupuncture at acupoints on the non-affected meridian (NAM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Acupuncture at non-acupoint (NA)
Number of subjects: 404

Group type: COMPARATOR
Intervention: No intervention (wait-listed group)
Number of subjects: 404
Study: 21849640

Group type: EXPERIMENTAL
Intervention: CS-positive patients
Number of subjects: 314

Group type: COMPARATOR
Intervention: CS-negative patients
Number of subjects: 314
Study: 19827461

Group type: COMPARATOR
Intervention: Control diet (CD), 5.5 +/- 0.3 g/d of L-arginine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diet 2 (same as CD but including an oral supplement of 15 g/d), 20.5 +/- 0.3 g/d of L-arginine
Number of subjects: 9
Study: 17341512

Group type: EXPERIMENTAL
Intervention: Craniocervical flexor training
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Endurance-strength training of the cervical flexor muscles
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68